US Broker Ratings

Centessa Pharmaceuticals (CNTA) Stock Analysis: A Promising Biotech with 23.88% Potential Upside

Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage biotechnology company, has been capturing investor interest with its innovative approach to drug development and a promising pipeline that targets a range of..

The Pennant Group, Inc. (PNTG) Stock Analysis: Strong Revenue Growth and a 25% Upside Potential

The Pennant Group, Inc. (NASDAQ: PNTG) is gaining traction in the healthcare sector, particularly within the medical care facilities industry. Investors are keeping a keen eye on this Eagle, Idaho-based..

Phreesia, Inc. (PHR) Stock Report: Analyzing a Promising 65.50% Upside with Robust Analyst Support

Phreesia, Inc. (PHR) is making waves in the healthcare sector with its innovative software-as-a-service (SaaS) platform aimed at enhancing the efficiency of healthcare processes. As a leader in health information..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Unveiling Growth Potential in the Biotech Sector

Tarsus Pharmaceuticals, Inc. (TARS) is capturing the attention of investors with its strategic focus on eye care therapeutics, a promising niche within the healthcare sector. As a commercial stage biopharmaceutical..

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Navigating the Biotech Wave with a 46% Potential Upside

As Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) continues to make strides in the biotechnology sector, investors are keenly watching its stock performance, buoyed by a potential upside of 46.27%. This clinical-stage..

Travere Therapeutics (TVTX) Stock Analysis: Unveiling a 15.95% Potential Upside in the Biotech Arena

Travere Therapeutics, Inc. (NASDAQ: TVTX) is capturing the attention of investors with its remarkable growth story in the dynamic healthcare sector. With a market capitalization of $3.2 billion, this San..

BioLife Solutions, Inc. (BLFS) Investor Outlook: Analysts See 21.82% Upside Potential

BioLife Solutions, Inc. (BLFS), a key player in the healthcare sector specializing in medical instruments and supplies, is making a significant mark within the cell and gene therapy industry. Headquartered..

Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Analyzing a 23% Potential Upside in the Biotech Sector

Viridian Therapeutics, Inc. (NASDAQ: VRDN) stands out in the biotechnology industry, not only for its innovative approach to treating serious and rare diseases but also for its potential investment upside...

Viking Therapeutics, Inc. (VKTX): Analyst Consensus Points to a Remarkable 169% Upside

Viking Therapeutics, Inc. (NASDAQ: VKTX) is capturing the attention of investors with its strong potential for growth in the biotechnology sector. Headquartered in San Diego, California, this clinical-stage biopharmaceutical company..

SS Innovations International (SSII) Stock Analysis: A Surge in Revenue Growth Amidst Volatile Market Conditions

SS Innovations International Inc. (SSII) is making waves in the healthcare sector, particularly in the medical devices industry. Headquartered in Gurugram, India, SSII is primarily known for its cutting-edge surgical..

CG Oncology, Inc. (CGON)

⚠️ No article content returned.

..

Beam Therapeutics Inc. (BEAM) Stock Report: Analyst Ratings Reveal Potential 94% Upside

Beam Therapeutics Inc. (NASDAQ: BEAM) is a biotechnology company that has captured investor attention with its focus on precision genetic medicines targeting serious diseases. Based in Cambridge, Massachusetts, Beam is..

Evotec SE (EVO) Stock Analysis: Exploring an 80.96% Upside Potential in the Healthcare Sector

Evotec SE (EVO), a prominent player in the healthcare industry, is making waves among investors with a significant potential upside of 80.96%. With a market capitalization of $1.08 billion and..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring an 89% Potential Upside Amidst Analyst Optimism

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is captivating the attention of investors with a compelling narrative in the biotechnology sector, particularly in the field of ophthalmology. With a market capitalization of..

Harrow, Inc. (HROW) Stock Analysis: A Promising 81% Upside in the Booming Eyecare Market

Harrow, Inc. (NASDAQ: HROW), a dynamic player in the eyecare pharmaceutical sector, has been capturing the attention of investors with its impressive growth trajectory and robust product portfolio. Headquartered in..

Protagonist Therapeutics (PTGX) Stock Analysis: A Biotech Venture with a $5.48 Billion Market Cap and Promising Clinical Trials

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) stands out in the biotechnology sector with its robust market capitalization of $5.48 billion, positioning itself as a noteworthy player in the healthcare industry. With..

Integra LifeSciences Holdings (IART) Investor Outlook: Is There a 24.2% Upside on the Horizon?

As the healthcare sector continues to evolve, investors are keeping a close eye on Integra LifeSciences Holdings Corporation (NASDAQ: IART), a prominent player in the medical devices industry. With a..

Galapagos NV (GLPG) Stock Analysis: Navigating the Biotech Waters with a 12% Downside

Investors eyeing the biotechnology sector often seek innovative companies with promising pipelines and strategic partnerships. Galapagos NV (GLPG), a Belgian biotech firm specializing in oncology and immunology, presents such opportunities,..

Establishment Labs Holdings Inc (ESTA) Stock Analysis: A Healthcare Innovator with 7.35% Potential Upside

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a pioneering medical technology company in the healthcare sector, has been making waves with its innovative products in the realm of aesthetic and reconstructive..

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Exploring an 82.97% Potential Upside in the Biotech Arena

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is garnering attention in the biotechnology sector with its focus on pioneering treatments for rare endocrine diseases and tumors. This clinical-stage pharmaceutical company, headquartered in..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds